From: The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer
Characteristicsa | N (%) |
---|---|
Age (mean ± SD and range) | 59.2 ± 13.2 (35–102 yrs) |
Gender | |
Male | 1 (0.9%) |
Female | 107 (99.1%) |
Histology | |
Ductal | 95 (88.0%) |
Other | 13 (12.0%) |
Grade | |
I | 7 (6.6%) |
II | 36 (34.0%) |
III | 63 (59.4%) |
Stage | |
0 | 3 (2.8%) |
I | 34 (31.8%) |
II | 46 (43.0%) |
III | 24 (22.4%) |
ER | |
Negative | 48 (44.4%) |
Positive | 60 (55.6%) |
PR | |
Negative | 40 (37.0%) |
Positive | 68 (63.0%) |
Her2 | |
Negative | 53 (49.1%) |
Positive | 55 (50.9%) |
Molecular subtype | |
Luminal A | 36 (33.3%) |
Luminal B | 38 (35.3%) |
ER-, PR-, Her2+ | 17 (15.7%) |
ER-, PR-, Her2- | 17 (15.7%) |
Regional lymph node involvement | |
No | 62 (58.5%) |
Yes | 44 (41.5%) |
Relapse | |
No | 71 (65.7%) |
Yes | 37 (34.3%) |
RFS duration median (range) | 54.6 (1.1 ~ 100.9 months) |
Outcomes | |
Alive | 100 (92.5%) |
Dead | 8 (7.5%) |
OS duration median (range) | 63.2 (1.6 ~ 217.9 months) |